Dennis Huang | Chief Technical Operations Officer and Executive Vice President, Gene Therapy Research and Development
Ultragenyx

Mr. Huang joined Ultragenyx in May 2015 and is responsible for leading global technical and pharmaceutical development, manufacturing and supply chain functions covering broad technical modalities including small molecules, recombinant proteins, nucleic acid medicines, and AAV gene therapy. This includes all clinical supply, product approvals and launches for Mepsevii ®, Crysvita® and Dojolvi®. In addition, Mr. Huang is the executive team member responsible for the Gene Therapy Platform strategy, research, product development, manufacturing, and supply chain. Prior to joining Ultragenyx, Mr. Huang was Senior Vice President of Manufacturing and Supply Chain for InterMune Inc., where he led the global manufacturing and supply chain organization for the company which led to the US approval of Esbriet ®. Prior to InterMune, he served as Vice President of Biologics Manufacturing and Development for Allergan, Inc. where he held dual responsibilities in R&D and Global Technical Operations. Earlier in his career, Mr. Huang held leadership positions at Novartis AG (formerly Chiron Corporation), Genentech, Inc., and Synergen (currently Amgen), where he worked in various roles including manufacturing, quality and process and analytical development. Mr. Huang serves on the Board of Directors of Ornovi, a privately held biotech company and MassBio, a not-for-profit Massachusetts life sciences biotech trade association.  Mr. Huang earned a B.A. in chemistry from Knox College. https://www.ultragenyx.com/leaders/dennis-huang/